Navigation Links
Cytopia's CYT387 Receives FDA Clearance to Start US Clinical Trials
Date:9/3/2009

mmittee approval.

"Approval of the company's second IND marks another milestone in the development of Cytopia's suite of small molecule drugs," said Mr. Andrew Macdonald, CEO. "With a strong package of preclinical data, the prospects for CYT387 are excellent and we look forward to commencing the clinical trial with Dr. Tefferi at the Mayo Clinic later this year."

There has been considerable commercial interest in the JAK2 target with no selective JAK inhibitors having yet successfully completed late stage clinical trials and few compounds in development that meet a desirable product profile. Cytopia will seek to develop CYT387 through a commercial partnership and has been in discussions with potential partners for some time. A similar JAK2 inhibitor in clinical development was recently licensed by Onyx Pharmaceuticals for $550 million including a $25 million up-front payment and double-digit royalties.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and California, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialled in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK1/JAK2 inhibitor focused on the treatment of myeloproliferative disorders, to enter Phase I clinical studies in 2009.

www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
2. Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy
3. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
4. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
5. Covance Receives Highest Level of Phase I Accreditation
6. Worlds First Cardiac Adult Stem Cell Patient Receives Infusion
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
9. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
10. USC Keck School of Medicines Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic
11. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2010)... Fourteenth Annual New York Emerging Growth Institutional Investor Forum at The Grand Hyatt in New York City on Tuesday, March 23, 2010 . , ... , , ... ... ...
(Date:3/17/2010)... Access MediQuip, LLC, the nation,s first and largest provider of outsourced implantable medical device management ... "RMS," for its customers nationwide. The new release is designed to protect patients, inform and ... ... ...
(Date:3/17/2010)... based on the,following elements: ,, ... , , ... ... "As former Vice-President for clinical drug development with a ...
Breaking Medicine Technology:Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum 2Access MediQuip Announces Release of the Country's First Centralized Recall Management Service(SM) for Implantable Devices 2Access MediQuip Announces Release of the Country's First Centralized Recall Management Service(SM) for Implantable Devices 3Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core Capabilities 2Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core Capabilities 3Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core Capabilities 4American Laser Centers Names Health Care Veteran Steven Straus CEO 59137 1American Laser Centers Names Health Care Veteran Steven Straus CEO 59137 2Deloitte Recap Launches New Series of Biopharmaceutical Business Intelligence Tools 14396 1Deloitte Recap Launches New Series of Biopharmaceutical Business Intelligence Tools 14396 2Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference 5333 1Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference 5333 2
(Date:3/18/2010)... State Leaders Urged to Support Higher Tobacco Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... WASHINGTON , March 18 ...
(Date:3/18/2010)... scientists from the Cedars-Sinai Heart Institute presented new findings ... heart disease, a drug therapy for atrial fibrillation and ... in weight reduction for obese patients with chronic end-stage ... These presentations were made at the American College of ...
(Date:3/18/2010)... March 18 Yesterday, Idaho became the ... protect their citizens from being forced to purchase health insurance ... The American Legislative Exchange Council (ALEC) has identified ... or have announced that they will introduce this legislation. Already, ...
(Date:3/18/2010)... ... , ... ... WASHINGTON , March 18 S.T.O.P. - Safe Tables Our Priority and victims of foodborne illness called upon the United States Department of ...
(Date:3/18/2010)... men appear to be beneficial, study finds , , THURSDAY, ... that older men with higher levels of selenium are ... metabolism. , Tasnime Akbaraly, from the University of Montpellier ... nine years, checking their levels of selenium and monitoring ...
Breaking Medicine News(10 mins):Health News:Montana Kids 'Kick Butts' on March 24 2Health News:Montana Kids 'Kick Butts' on March 24 3Health News:Montana Kids 'Kick Butts' on March 24 4Health News:Montana Kids 'Kick Butts' on March 24 5Health News:Cedars-Sinai Heart Institute physicians present findings at ACC scientific meeting 2Health News:Cedars-Sinai Heart Institute physicians present findings at ACC scientific meeting 3Health News:Idaho Enacts Health Care Freedom Act 2Health News:Idaho Enacts Health Care Freedom Act 3Health News:Idaho Enacts Health Care Freedom Act 4Health News:Idaho Enacts Health Care Freedom Act 5Health News:Victims of Contaminated Meat Call on USDA to Address Deadly Pathogens 2Health News:Victims of Contaminated Meat Call on USDA to Address Deadly Pathogens 3
... WASHINGTON, Jan. 3 Continuing its role ... provider organizations, the,American Association of Preferred Provider ... Health Care Administrators Association,(HCAA) that will significantly ... Competition, consolidation and increased consumerism continue to ...
... and depression, even though it doesn,t impact on hot flashes, ... Exercise is not a cure for hot flashes, but it ... a Pennsylvania study has found. , The researchers had hoped ... to hormone replacement therapy for women suffering from hot flashes, ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the ... received approval from the U.S. Food and Drug Administration ... deficit hyperactivity disorder (ADHD) treatment, VYVANSE™ (lisdexamfetamine dimesylate). Shire ... 40 mg and 60 mg will be available in ...
... on Body Image, Cancer, and Breast-feeding Examined, ... re-evaluating past scientific findings and developing new,knowledge about ... to Plastic and Reconstructive Surgery(R) (PRS), the official,medical ... (ASPS), sheds,new light on the psychological impact and ...
... Foods Debuts Five Great-Tasting Potato, Chip Flavors Featuring ... ... Regular Potato Chips, LOS ANGELES, Jan. 3 ... the all-American,classic potato chip into a heart-healthy culinary delight ...
... era of expanding competition,from generics, expiring patent protection ... drug discoveries, there is very little margin for ... Kalorama Information entitled Drug,Pricing and Reimbursement Strategies: Preparing ... information they need to,reevaluate their pricing strategies to ...
Other Medicine News:Health News:AAPPO and HCAA Form Partnership to Enhance Services to Meet the Changing Business Needs of PPOs and TPAs 2Health News:Exercise Eases Some Menopause Symptoms 2Health News:Exercise Eases Some Menopause Symptoms 3Health News:FDA approves additional dosage strengths of Vyvanse 2Health News:ASPS Studies Re-Evaluate Psychological Benefits and Health Concerns of Silicone Breast Implants 2Health News:Corazonas Launches First and Only Cholesterol-Reducing Potato Chips 2Health News:Generic Onslaught Makes Drug Pricing Decisions More Critical Than Ever 2
... Ring Pessary is specifically ... urinary stress incontinence. The ... by stabilizing the bladder ... enhancement of urethral resistance ...
The Incontinence Dish is used to relieve stress incontinence and minor degrees of prolapse. The Incontinence Dish comes with and without support. It is available in eight different sizes....
... The ring pessary, available in ... without support, is a very ... to second degree prolapse. The ... be used on an accompanying ...
Low Profile Design for Precise Anchor Placement...
Medicine Products: